LAPTM4B-35蛋白作为肝癌血清学诊断新标志物的探讨

doi:10.19723/j.issn.1671-167X.2021.04.015

摘要/Abstract

摘要：

目的: LAPTM4B-35是北京大学基础医学院发现和鉴定的一个肿瘤驱动基因LAPTM4B所编码的蛋白质同型分子(isoform)之一,其在多种恶性肿瘤中[如肝癌、肺癌(包括非小细胞肺癌和小细胞肺癌)、胃癌、结直肠癌、胰腺癌、胆囊癌、胆管癌、乳腺癌、前列腺癌、宫颈癌、子宫内膜癌等]均超高表达。实验室和临床资料均证明,LAPTM4B-35蛋白的过表达促进肿瘤生长、转移和多药耐药,LAPTM4B-35的蛋白表达水平与肝癌的复发相关。本文的目的在于鉴定患者体内的肝癌细胞和体外培养的肝癌细胞系是否释放出LAPTM4B-35蛋白到血液和细胞培养液中,以及其可能的存在形式,为建立肝细胞癌等肿瘤的血清学诊断新方法奠定基础。方法: 采用免疫印迹分析(Western blot)、酶联免疫吸附实验(enzyme-linked immunosorbent assay,ELISA)鉴定LAPTM4B-35蛋白,应用超滤和超离心方法从肝癌细胞培养上清液中分离、纯化外排体(exosome)。结果: 特异性抗体的ELISA结果表明,肝细胞癌患者的血液中存在LAPTM4B-35蛋白,体外培养的肝癌细胞以外排体形式释放LAPTM4B-35蛋白到培养基的上清液中。ELISA夹心法检测表明,肝细胞癌患者(n=43)血淸中LAPTM4B-35蛋白的平均水平和中位值均显著高于正常人(n=33)。结论: 肝癌细胞以外排体形式释放到其外环境中的LAPTM4B-35蛋白有望成为肝细胞癌血清学诊断的新标志物。

关键词: 肝细胞癌, 外排体, LAPTM4B-35, 生物标记, 肿瘤

Abstract:

Objective: LAPTM4B-35 protein is one of the isoforms that are encoded by a cancer driver gene, LAPTM4B. This gene was primarily found and identified in our lab of Peking University School of Basic Medical Sciences. The LAPTM4B-35 protein and its encoded mRNA are significantly over-expressed in a variety of cancers, such as hepatocellular carcinoma (HCC), lung cancers (including non small-cell lung cancer and small-cell lung cancer), stomach cancer, colorectal carcinoma, pancreatic cancer, gallbladder cancer, cholangiocarcinoma, breast cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, and so on. It has firmly demonstrated through lab experiments either in vivo or in vitro, as well as clinical studies that the over-expression of LAPTM4B-35 can promote cancer growth, metastasis, and multidrug resistance. Specially, the expressive level of LAPTM4B-35 is associa-ted with recurrence of HCC. The aim of this study is to identify the release of LAPTM4B-35 protein from hepatocellular carcinoma into blood of HCC patients and into the medium of cultured HCC cells, and to identify its possible form of LAPTM4B-35 protein existed in blood and cell culture medium, as well as to explore the possibility of LAPTM4B-35 protein as a novel HCC biomarker for diagnosis of HCC and prognosis of HCC patients. Methods: Immunobloting (Western blot) and enzyme-linked immunosorbent assay (ELISA) were used for identification of LAPTM4B-35 protein in the blood of HCC patients and normal individuals. Ultrafiltration and ultracentrifugation were used to isolate and purify exosomes from the culture medium of HCC cells. Results: LAPTM4B-35 protein existed in the blood from HCC patients and normal donors that were demonstrated through Western blot and ELISA. LAPTM4B-35 was also released into the culture medium of HCC cells in the form of exosomes. Preliminary experiments showed that the average and the median of LAPTM4B-35 protein level in the blood of HCC patients (n=43) were both significantly higher than that in the blood of normal donors (n=33) through sandwich ELISA. Conclusion: It is promising that the LAPTM4B-35 protein which is released from HCC cells in the form of exosomes into their extraenvironment may be exploited as a novel cancer biomarker for HCC serological diagnosis.

Key words: Hepatocellular carcinoma, Exosomes, LAPTM4B-35, Biomarkers, tumor

中图分类号:

R735.7

庞泳,张沙,杨华,周柔丽. LAPTM4B-35蛋白作为肝癌血清学诊断新标志物的探讨[J]. 北京大学学报（医学版）, 2021, 53(4): 710-715.

PANG Yong,ZHANG Sha,YANG Hua,ZHOU Rou-li. Serum LAPTM4B-35 protein as a novel diagnostic marker for hepatocellular carcinoma[J]. Journal of Peking University (Health Sciences), 2021, 53(4): 710-715.

图/表 6

图1

图2

图3

图4

图5

图6

参考文献 21

[1]	Shao GZ, Zhou RL, Zhang QY, et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma [J]. Oncogene, 2003, 22(32):5060-5069. doi: 10.1038/sj.onc.1206832
[2]	Yang H, Xiong FX, Lin M, et al. LAPTM4B-35 is a novel diagnostic marker and a prognostic factor of hepatocellular carcinoma [J]. J Surgical Oncology, 2010, 101(5):363-369. doi: 10.1002/jso.v101:5
[3]	Yang H, Xiong FX, Lin M, et al. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma [J]. J Cancer Res Clin Oncol, 2010, 136(2):275-281. doi: 10.1007/s00432-009-0659-4 pmid: 19690886
[4]	何静, 邵根泽, 周柔丽, 等. 肝癌中高表达的新基因LAPTM4B对细胞增殖及成瘤性的影响 [J]. 北京大学学报(医学版), 2003, 35(4):348-352.
[5]	Li L, Shan Y, Yang H, et al. Upregulation of LAPTM4B-35 promotes malignant transformation and tumorigenesis in L02 human liver cell line [J]. Anat Rec (Hoboken), 2011, 294(7):1135-1142. doi: 10.1002/ar.v294.7
[6]	Liu XR, Xiong FX, Wei XH, et al. LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of HCC cells [J]. Cancer Sci, 2009, 100(12):2335-2340. doi: 10.1111/cas.2009.100.issue-12
[7]	Li L, Wei XH, Pan YP, et al. LAPTM4B: A novel cancer-asso-ciated gene motivates multi-drug resistance through efflux and activating PI3K/Akt signaling [J]. Oncogene, 2010, 29(43):5785-5795. doi: 10.1038/onc.2010.303 pmid: 20711237
[8]	Yang H, Xiong FX, Wei XH, et al. LAPTM4B-35 promotes growth and metastasis of hepatocelluar carcinoma [J]. Cancer Lett, 2010, 264(2):209-217. doi: 10.1016/j.canlet.2008.01.025
[9]	刘歆荣, 周柔丽, 张青云, 等. 人肝癌相关新基因编码产物LAPTM4B的鉴定及其生物学特性 [J]. 北京大学学报(医学版), 2003, 35(4):340-347.
[10]	Keller S, Sanderson MP, Stoeck A, et al. Exosomes: from biogenesis and secretion to biological function [J]. Immunol Lett, 2006, 107(2):102-108. doi: 10.1016/j.imlet.2006.09.005
[11]	Simons M, Raposo G. Exosomes: vesicular carriers for intercellular communication [J]. Curr Opin Cell Biol, 2009, 21(4):575-581. doi: 10.1016/j.ceb.2009.03.007
[12]	Simpson RJ. Exosomes: proteomic insights and diagnostic potential [J]. Expert Rev Proteomics, 2009, 6(3):267-283. doi: 10.1586/epr.09.17
[13]	Mitchell PJ, Welton J, Staffurth J. Can urinary exosomes act as treatment response markers in prostate cancer? [J]. J Transl Med, 2009, 7:4. doi: 10.1186/1479-5876-7-4 pmid: 19138409
[14]	Nilsson J, Skog J, Nordstrand A, et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer [J]. Br J Cancer, 2009, 100(10):1603-1607. doi: 10.1038/sj.bjc.6605058
[15]	Théry C, Amigorena S, Raposo G, et al. Isolation and characte-rization of exosomes from cell culture supernatants and biological fluids [J]. Curr Protoc Cell Biol, 2006, Chapter 3: Unit 3.22.
[16]	Navabi H, Croston D, Hobot J, et al. Preperation of human ova-rian cancer ascites-derived exosomes for a clinical trial [J]. Blood Cells Mol Dis, 2005, 35(2):149-152. doi: 10.1016/j.bcmd.2005.06.008
[17]	Houali K, Wang X, Shimizu Y, et al. A new diagnostic marker for secreted Epstein-Barr virus encoded LMP1 and BARF1, oncoproteins in the serum and saliva of patients with nasopharyn-geal carcinoma [J]. Clin Cancer Res, 2007, 13(17):4993-5000. pmid: 17785549
[18]	Viaud S, Théry C, Ploix S, et al. Dendritic cell-derived exosomes for cancer immunotherapy: what’s next? [J]. Cancer Res, 2010, 70(4):1281-1285. doi: 10.1158/0008-5472.CAN-09-3276
[19]	Koga K, Matsumoto K, Akiyoshi T, et al. Purification, characte-rization and biological significance of tumor-derived exosomes [J]. Anticancer Res, 2005, 25(6A):3703-3707.
[20]	Zhou RL. LAPTM4B: a novel diagnostic biomarker and therapeutic target for hepatocellular carcinoma [M]// Wan-Yee Lau. Hepatocellular carcinoma: Basic research. Philippines: InTech Press, 2012: 1-34.
[21]	Yang Z, Senninger N, Flammang I, et al. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma [J]. J Cancer Res Clin Oncol, 2019, 145(5):1165-1178. doi: 10.1007/s00432-019-02863-w

相关文章 15

[1]	季加孚, 韦静涛, 季科, 步召德. 胃癌诊疗的瓶颈与破局：迈向精准化与智能化融合的新纪元[J]. 北京大学学报（医学版）, 2026, 58(2): 231-238.
[2]	高加勒, 张忠涛. 局部进展期直肠癌精准治疗现状与展望[J]. 北京大学学报（医学版）, 2026, 58(2): 247-250.
[3]	王海, 江一舟. 靶向血管治疗在乳腺癌精准治疗中的分子机制与临床应用[J]. 北京大学学报（医学版）, 2026, 58(2): 251-256.
[4]	罗必显, 刘洪铭, 谢伟勋, 龚渭华. 产甲胎蛋白胃癌的新临床特征和前沿科学问题[J]. 北京大学学报（医学版）, 2026, 58(2): 257-265.
[5]	杜文, 章文博, 于尧, 刘硕, 苏惠裕, 胡耒豪, 唐祖南, 吴彬彰, 陈震, 李家琦, 王昊, 彭歆. 口腔颌面部肿瘤"数智化外科"诊疗流程探索与临床应用[J]. 北京大学学报（医学版）, 2026, 58(2): 278-284.
[6]	王楠楠, 袁大晋, 朱昱冰, 丁磊. 结直肠癌根治术后肝转移风险多中心列线图预测模型的构建与验证[J]. 北京大学学报（医学版）, 2026, 58(2): 290-300.
[7]	刘友东, 吕亚军, 陈杰, 臧明德, 潘宏达, 刘晓文, 陆俊, 刘凤林. 全腹腔镜保留贲门胃底胃次全切除术治疗中上部胃癌的疗效及安全性[J]. 北京大学学报（医学版）, 2026, 58(2): 301-306.
[8]	李嘉临, 陈力侨, 唐家天, 吴艳, 王安强. 胃肝样腺癌转化治疗1例[J]. 北京大学学报（医学版）, 2026, 58(2): 399-404.
[9]	李斌, 梁寒. 机器人胃癌根治术：研究进展与实践挑战[J]. 北京大学学报（医学版）, 2026, 58(2): 416-422.
[10]	董海峰, 陈恒星, 张常华. 恶性肿瘤中蛋白质乳酸化修饰的研究进展[J]. 北京大学学报（医学版）, 2026, 58(2): 423-430.
[11]	李宏杨, 黄涛, 王琳琳. 脂肪肌肉比率与卵巢良性肿瘤风险的关联性[J]. 北京大学学报（医学版）, 2026, 58(1): 169-174.
[12]	高若凡, 马天宇, 王润楷, 殷雨辰, 李芮迪, 王丹丹, 夏斌. 细胞膜囊泡递送靶向肿瘤坏死因子-α的小干扰RNA对牙髓干细胞的抗炎作用[J]. 北京大学学报（医学版）, 2026, 58(1): 22-29.
[13]	向钊, 杨莉, 杨静. 非靶向代谢组学揭示原发性干燥综合征血小板减少患者血清差异代谢物及代谢通路[J]. 北京大学学报（医学版）, 2025, 57(6): 1042-1050.
[14]	刘艳华, 陆敏, 赵旭阳, 张宽根, 武睿, 梅放, 戴志豪, 由江峰, 裴斐. 肿瘤转移抑制基因LASS2去磷酸化对液泡型ATP酶活性及前列腺癌侵袭性的影响[J]. 北京大学学报（医学版）, 2025, 57(6): 1113-1123.
[15]	杨小勇, 张帆, 马潞林, 刘承. 前列腺导管腺癌临床特征及腺外侵犯的影响因素[J]. 北京大学学报（医学版）, 2025, 57(5): 956-960.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed